Diazepam during prior ethanol withdrawals does not alter seizure susceptibility during a subsequent withdrawal.
The number of cycles of alcohol detoxification is suggested to be an important variable in the predisposition to severe withdrawal seizures in alcohol-dependent individuals. Several clinical studies have suggested that exposure to repeated alcohol withdrawals may lead to increased severity of subsequent withdrawal episodes. Consistent with these observations, exposure to multiple cycles of ethanol withdrawal in our previous study significantly increased sensitivity to the convulsive effects of the GABA(A) receptor inverse agonist, Ro15-4513, in comparison to continuous ethanol exposure with no intermittent withdrawals. There was also a selective increase in the occurrence of spontaneous spike and sharp wave (SSW) activity in the EEG recorded from hippocampal area CA(3) in proportion to the number of withdrawal episodes experienced. It is hypothesized that during such repeated episodes of ethanol intoxication and withdrawal, changes in neuronal excitation during prior withdrawals could serve as initially subconvulsive kindling stimuli that might eventually result in the increased severity of the withdrawal syndrome. There is some evidence of the successful suppression of such neuronal excitation during acute ethanol withdrawal by positive modulators of the GABA(A) receptor. In the present study, the benzodiazepine agonist, diazepam, at a dose (4.0 mg/kg) that suppresses acute withdrawal symptoms, when administered during intermittent withdrawals, did not alter seizure sensitivity during a subsequent nonmedicated withdrawal. Diazepam treatment during prior withdrawals also did not have any effect on the multiple withdrawal-associated increase in SSW activity in hippocampal area CA(3) during an untreated withdrawal. This finding suggests that suppression of acute withdrawal symptoms by diazepam does not prevent long-lasting changes in CNS function resulting from repeated exposures to ethanol withdrawal.
Department of Psychiatry and Behavioral Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190-3000, USA.
M C
MC
Mhatre
S E
SE
McKenzie
L P
LP
Gonzalez
D000345:Affinity Labels / Q000009:adverse effects; D020270:Alcohol Withdrawal Seizures / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D001386:Azides / Q000009:adverse effects; D001569:Benzodiazepines / Q000009:adverse effects; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D002492:Central Nervous System Depressants / Q000009:adverse effects* / Q000097:blood; D003975:Diazepam / Q000627:therapeutic use*; D004569:Electroencephalography; D000431:Ethanol / Q000009:adverse effects* / Q000097:blood; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley
D000345:Affinity Labels; D000927:Anticonvulsants; D001386:Azides; D002492:Central Nervous System Depressants; D001569:Benzodiazepines; D000431:Ethanol; C042957:Ro 15-4513; D003975:Diazepam